The Genetics Navigator: A novel digital tool to advance quality and equity in genomic medicine

  • Funded by Canadian Institutes of Health Research (CIHR)
  • Total publications:0 publications

Grant number: 202010PJM

Grant search

Key facts

  • Disease

    COVID-19
  • Start & end year

    2020
    2021
  • Known Financial Commitments (USD)

    $75,000
  • Funder

    Canadian Institutes of Health Research (CIHR)
  • Principal Investigator

    N/A

  • Research Location

    Canada
  • Lead Research Institution

    Unity Health Toronto
  • Research Priority Alignment

    N/A
  • Research Category

    Secondary impacts of disease, response & control measures

  • Research Subcategory

    Indirect health impacts

  • Special Interest Tags

    Digital Health

  • Study Type

    Clinical

  • Clinical Trial Details

    Randomized Controlled Trial

  • Broad Policy Alignment

    Pending

  • Age Group

    Unspecified

  • Vulnerable Population

    Unspecified

  • Occupations of Interest

    Unspecified

Abstract

Genome-wide sequencing (GS) is increasingly being used in routine medical care as it improves diagnosis and informs treatment. However, GS is a complex and costly service. This results in unequal access, increased wait times and inconsistencies in care. The use of digital tools to support genetic service delivery can result in a better patient experience and reduced distress associated with waiting for results and empower patients to act on medical results. Our study will develop a patient centred digital platform - The Genetics Navigator - to deliver genetic testing services and then evaluate its feasibility and effectiveness compared to usual care. The platform will include innovative strategies for pre-and post-test genetic counselling and result reporting. First, we will identify the key components of this novel digital platform and then build the educational, decisional and emotional support components. We will then conduct usability testing with a pan-Canadian sample of patients and health care providers to ensure the platform is patient-centred and optimized for a range of clinical settings. Next, we will conduct a pilot randomized controlled trial, to understand if the Genetics Navigator is feasible to use and better than usual care. Patients undergoing genetic testing will be randomly assigned to use either the Genetics Navigator or usual care that consists of meeting with genetics providers in-person. The outcomes related to feasibility include acceptability, satisfaction, and patient engagement and the outcomes related to effectiveness include patients' distress, empowerment, knowledge, and behaviour change. This study represents a significant advance in health service delivery by developing a novel, comprehensive digital platform to improve patient experience, access to less well-served communities, and clinical workflow efficiency. The shift to virtual care during the COVID-19 pandemic underscores the critical importance of this work.